Back to News
Market Impact: 0.3
Abeona Therapeutics (ABEO) Highlights FDA Approval Of FAYUVI Gene Therapy For MPS IIIA
Source: Nasdaq
Healthcare & Biotech
The FDA approved Ultragenyx Pharmaceutical's FAYUVI (rebisufligene etisparvovec-hopf/UX111) to treat Sanfilippo syndrome type A (MPS IIIA). Abeona Therapeutics publicly congratulated Ultragenyx on the approval, which represents a positive regulatory milestone in rare-disease gene therapy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
ABEO0.10
RARE0.85
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Bright Minds shares fall as BTIG cuts price target on clinical hold
- Vertex Pharma meets Q3 estimates, raises revenue guidance
- Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future